Your browser is no longer supported. Please, upgrade your browser.
AZN AstraZeneca PLC weekly Stock Chart
AstraZeneca PLC
Index- P/E51.75 EPS (ttm)0.86 Insider Own0.50% Shs Outstand2.62B Perf Week3.99%
Market Cap116.97B Forward P/E22.16 EPS next Y2.01 Insider Trans0.00% Shs Float2.61B Perf Month-0.02%
Income2.19B PEG3.30 EPS next Q0.42 Inst Own18.90% Short Float0.55% Perf Quarter7.21%
Sales23.07B P/S5.07 EPS this Y-9.60% Inst Trans-1.58% Short Ratio4.48 Perf Half Y3.86%
Book/sh5.17 P/B8.63 EPS next Y11.52% ROA3.60% Target Price46.14 Perf Year18.99%
Cash/sh2.38 P/C18.72 EPS next 5Y15.70% ROE18.10% 52W Range35.30 - 45.69 Perf YTD17.46%
Dividend1.40 P/FCF- EPS past 5Y-3.60% ROI10.90% 52W High-1.46% Beta0.45
Dividend %3.14% Quick Ratio0.70 Sales past 5Y-3.10% Gross Margin80.30% 52W Low27.55% ATR0.69
Employees64400 Current Ratio0.90 Sales Q/Q13.00% Oper. Margin15.20% RSI (14)62.08 Volatility1.04% 1.13%
OptionableYes Debt/Eq1.45 EPS Q/Q-64.10% Profit Margin9.50% Rel Volume1.51 Prev Close44.61
ShortableYes LT Debt/Eq1.32 EarningsOct 24 BMO Payout161.60% Avg Volume3.19M Price45.03
Recom1.60 SMA201.78% SMA503.73% SMA20011.70% Volume3,219,633 Change0.93%
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Dec-29-17Upgrade JP Morgan Neutral → Overweight
Oct-16-17Upgrade Credit Suisse Neutral → Outperform
Sep-25-17Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17Upgrade Bernstein Mkt Perform → Outperform
Sep-14-17Downgrade Liberum Buy → Hold
Sep-06-17Upgrade Natixis Bleichroeder Neutral → Buy
Aug-09-17Upgrade Investec Hold → Buy
Jul-28-17Downgrade Morgan Stanley Overweight → Equal-Weight
May-12-17Upgrade Credit Suisse Underperform → Neutral
Apr-10-17Downgrade Jefferies Buy → Hold
Sep-20-19 11:54AM  FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD Zacks
08:41AM  Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates Zacks
Sep-19-19 02:31PM  Ironwood Amends Linzess Agreement with AstraZeneca in China Zacks
12:46PM  U.K. stocks snap three-day losing run MarketWatch
Sep-16-19 10:43AM  AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure Zacks
10:16AM  Biogen Stops Late-Stage Studies on Alzheimer's Candidate Zacks
08:33AM  Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert Zacks
07:30AM  FDA Grants Fast Track Designation for FARXIGA in Heart Failure Business Wire
03:23AM  AstraZeneca diabetes drug granted fast track status for heart failure treatment Reuters
Sep-13-19 10:08AM  Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use Zacks
09:46AM  Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others Zacks
04:47AM  Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised) Zacks
Sep-12-19 05:46PM  Gilead Tops List of Most Innovative Drug Companies
09:09AM  Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug Zacks
Sep-11-19 05:47PM  East Bay company eyes first drug approval after decade-long journey American City Business Journals
03:50PM  Leaner Pfizer Positioned to Boost R&D Output
11:40AM  AVEO Surges on Favorable Updated OS Results on RCC Drug Zacks
11:13AM  Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit Zacks
09:46AM  Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally Zacks
09:32AM  4 Big Drugmakers Boasting Impressive Oncology Pipelines Zacks
08:57AM  Should You Buy AstraZeneca PLC (LON:AZN) For Its Dividend? Simply Wall St.
Sep-10-19 11:41AM  ACADIA Surges on Early Success of Nuplazid Dementia Study Zacks
Sep-09-19 09:32PM  AstraZeneca's Executive VP Sees Upside, As China's Government Speeds Up New Drug Approval Bloomberg
07:00AM  IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer Business Wire
03:38AM  CORRECTED-AstraZeneca's Imfinzi prolongs survival in aggressive lung cancer Reuters
Sep-06-19 11:48AM  Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA Zacks
11:36AM  Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs Zacks
08:39AM  Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer Zacks
Sep-05-19 01:50PM  AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC Zacks
12:52PM  Podcast: Why Big Pharma Is Betting on a New Biotech Therapy
11:12AM  Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? Motley Fool
Sep-04-19 10:32AM  Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M Zacks
Sep-03-19 03:05PM  5 things to know ahead of Viela Bios planned $150M IPO American City Business Journals
10:44AM  Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded Yahoo Finance
10:26AM  Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded Yahoo Finance Video
Sep-02-19 03:13PM  The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight Benzinga
07:30AM  Pound tumbles as British factory output hits seven-year low ahead of Brexit showdown MarketWatch
12:53AM  Marks and Spencer heads for relegation from FTSE 100 Financial Times
Aug-30-19 02:56PM  Md. biotech files to go public with $150M offering American City Business Journals
01:50PM  AstraZeneca Spin-Off Viela Bio Files For IPO Benzinga
11:16AM  AstraZeneca's Lupus Drug Meets Primary Endpoint in Study Zacks
10:11AM  Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs Zacks
Aug-29-19 09:06AM  Forget Pfizer, Add These Big Drugmakers to Your Portfolio Zacks
Aug-28-19 10:21AM  AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease Zacks
10:18AM  AstraZeneca respiratory business gets boost from 3-drug inhaler results Reuters
10:10AM  Here's Why Merck (MRK) is Outperforming Its Industry Of Late Zacks
07:00AM  PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease Business Wire
03:13AM  UPDATE 2-AstraZeneca respiratory business gets boost from 3-drug inhaler results Reuters
02:32AM  U.S. FDA grants orphan drug status to AstraZeneca's asthma drug Fasenra Reuters
Aug-27-19 02:46PM  Viela Bio clears another hurdle to get rare disease drug to market American City Business Journals
11:32AM  AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome Zacks
07:00AM  FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease Business Wire
02:55AM  UPDATE 1-U.S. FDA gives fast track status to AstraZeneca's diabetes drug Farxiga Reuters
02:31AM  AstraZeneca says U.S. FDA grants fast track status for diabetes drug Farxiga Reuters
Aug-26-19 04:49PM  Inovio (INO) Down More Than 30% in 3 Months: Here's Why Zacks
Aug-24-19 03:04PM  Bulls And Bears Of The Week: Chevron, Disney, Target And More Benzinga
01:46PM  10 Biopharmaceutical Companies Trying To Cure Cancer Benzinga
04:55AM  We Think AstraZeneca (LON:AZN) Can Stay On Top Of Its Debt Simply Wall St.
Aug-23-19 09:40AM  Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit Zacks
08:27AM  Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer Zacks
Aug-22-19 06:08PM  AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China Zacks
07:18AM  The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study Benzinga
Aug-21-19 10:50AM  AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study Zacks
09:04AM  AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study Benzinga
07:35AM  UPDATE 2-AstraZeneca Imfinzi combination fails advanced lung cancer study Reuters
02:52AM  AstraZeneca faces setback in lung cancer drug trial Financial Times
Aug-20-19 11:01AM  China adds 148 drugs to key insurance list - state media Reuters
07:00AM  FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure Business Wire
06:17AM  Sainsbury continues climb from 30-year low as FTSE 100 edges higher MarketWatch
05:34AM  Europe stocks stuck after two days of gains MarketWatch
04:15AM  UPDATE 2-European shares end lower as Italy's political crisis weighs Reuters
03:03AM  European shares rise for third straight session Reuters
Aug-16-19 11:28AM  Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY Zacks
10:33AM  AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL Zacks
09:00AM  Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC Zacks
Aug-15-19 10:30AM  Agios Rides High on Tibsovo Sales Amid Acute Competition Zacks
07:48AM  Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth Zacks
Aug-14-19 08:15AM  3 Healthcare Stocks at All-Time Highs: Are They Buys? Motley Fool
08:00AM  CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia Business Wire
07:00AM  LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer Business Wire
Aug-13-19 10:58AM  AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis Benzinga
Aug-12-19 10:47AM  Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises Zacks
02:26AM  No-deal Brexit could deepen Europe's shortage of medicines - experts Reuters
Aug-09-19 11:29AM  AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag Zacks
11:16AM  Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates Zacks
07:00AM  TAGRISSO® (OSIMERTINIB) Significantly Improves Overall Survival in the Phase III FLAURA Trial for 1st-line EGFR-mutated Non-small Cell Lung Cancer Business Wire
Aug-07-19 07:05AM  Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer GlobeNewswire
06:55AM  LYNPARZA® (Olaparib) Phase III Profound Trial in HRR* Mutation-Selected Metastatic Castration-Resistant Prostate Cancer Met Primary Endpoint Business Wire
Aug-06-19 04:37AM  The CEO Who Capped a $37 Billion Recovery With a Cancer Drug Deal Bloomberg
Aug-04-19 03:04PM  3 Lung Cancer Stocks That Could Soar in September Motley Fool
03:17AM  It Might Be Better To Avoid AstraZeneca PLC's (LON:AZN) Upcoming 1.0% Dividend Simply Wall St.
Jul-31-19 10:58AM  Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates Zacks
Jul-30-19 12:49PM  Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View Zacks
Jul-29-19 04:18AM  Edited Transcript of AZN.L earnings conference call or presentation 25-Jul-19 11:00am GMT Thomson Reuters StreetEvents
Jul-27-19 12:20PM  10 Biggest Cancer-Fighting Stocks Motley Fool
Jul-26-19 08:58AM  AstraZeneca (AZN) Jumps: Stock Rises 5.7% Zacks
08:39AM  Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment Zacks
Jul-25-19 04:29PM  Why AstraZeneca, Ambev, and Nokia Jumped Today Motley Fool +5.72%
04:14PM  Two Pharma Stocks Flew On Strong Quarters But Drug Stocks Slipped Investor's Business Daily
01:06PM  Pharma giants eye 'period of change' as drug pricing talk heats up in DC Yahoo Finance
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a collaboration and license option agreement with Transgene SA for clinical development and commercialization of novel oncolytic immunotherapies. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ASTRAZENECA PLC10% OwnerOct 22Buy5.00600,0003,000,0003,004,554Oct 24 04:16 PM
ASTRAZENECA PLC10% OwnerSep 28Buy15.00246,6663,699,9902,164,855Oct 02 09:35 PM